6-Heteroaryloxy-Quinoline-2-Carboxamides for Nav 1.7/1.8 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule blockers for voltage-gated sodium channels, such as Nav 1.7 and Nav 1.8, face challenges in achieving sufficient potency and selectivity for effective pain management, with existing compounds often having incomplete efficacy and poor tolerability.
Innovation Solution
Development of 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides that selectively block Nav 1.7 and Nav 1.8 channels, offering a new structural approach to treat various types of pain by modulating sodium channel activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing VGSC blockers (local anesthetics, anti-arrhythmic agents, anti-convulsants) are used for pain management, then they provide some therapeutic effect, but they exhibit poor selectivity versus Nav 1.x subtypes and other ion channels, leading to incomplete efficacy and poor tolerability
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features (6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamide structure) that confer selective affinity for Nav 1.7 and Nav 1.8 channels. The molecular structure contains specific functional groups and spatial arrangements that interact preferentially with these channel subtypes, providing localized selectivity at the molecular binding site level.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types (R1, R2, R3 groups), ring structures, and stereochemistry to optimize selectivity for Nav 1.7/1.8 channels. By adjusting these molecular parameters, the compounds achieve enhanced binding affinity and selectivity while maintaining acceptable pharmacological properties.
2Adaptability or versatility
If non-selective VGSC blockers are administered to achieve broad pain relief, then they may affect multiple ion channel types, but this results in poor tolerability and limited clinical utility
Solution Approach 1:
The compounds exhibit local quality through their selective molecular recognition of Nav 1.7 and Nav 1.8 channel subtypes. The 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamide core structure, combined with specific substituent patterns, creates a binding profile that is localized to these particular channel isoforms, sparing other ion channels from off-target effects.
Solution Approach 2:
The patent applies segmentation by targeting specific Nav channel subtypes (Nav 1.7 and Nav 1.8) rather than blocking all voltage-gated sodium channels. This subtype-specific approach segments the therapeutic action to affect only the channels most involved in pain pathways, avoiding the side effects associated with broader channel blockade.
3Reliability
If high doses of existing VGSC blockers are used to improve efficacy, then pain relief may be enhanced, but side effects and poor tolerability increase
Solution Approach 1:
The patent utilizes parameter changes by optimizing the molecular structure to achieve high binding affinity and selectivity for Nav 1.7/1.8 channels. This allows the compounds to produce therapeutic effects at lower concentrations, improving the therapeutic index by decoupling efficacy from dose-dependent side effects through enhanced molecular efficiency.
Data Source
AI summary
Compounds of formula (I)and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.